These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 23611619)
1. Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine. Ahmad Fuaad AA; Jia Z; Zaman M; Hartas J; Ziora ZM; Lin IC; Moyle PM; Batzloff MR; Good MF; Monteiro MJ; Skwarczynski M; Toth I Nanomedicine (Lond); 2014 Jan; 9(1):35-43. PubMed ID: 23611619 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in peptide-based subunit nanovaccines. Skwarczynski M; Toth I Nanomedicine (Lond); 2014 Dec; 9(17):2657-69. PubMed ID: 25529569 [TBL] [Abstract][Full Text] [Related]
3. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant. Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764 [TBL] [Abstract][Full Text] [Related]
4. Method for the synthesis of highly pure vaccines using the lipid core peptide system. Moyle PM; Olive C; Good MF; Toth I J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293 [TBL] [Abstract][Full Text] [Related]
5. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. Skwarczynski M; Toth I Methods Mol Biol; 2011; 751():297-308. PubMed ID: 21674338 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship of group A streptococcus lipopeptide vaccine candidates in trimethyl chitosan-based self-adjuvanting delivery system. Nevagi RJ; Dai W; Khalil ZG; Hussein WM; Capon RJ; Skwarczynski M; Toth I Eur J Med Chem; 2019 Oct; 179():100-108. PubMed ID: 31247372 [TBL] [Abstract][Full Text] [Related]
7. Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors. Lu J; Shi M; Shoichet MS Bioconjug Chem; 2009 Jan; 20(1):87-94. PubMed ID: 19099361 [TBL] [Abstract][Full Text] [Related]
8. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery. Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762 [TBL] [Abstract][Full Text] [Related]
9. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus. Simerska P; Abdel-Aal AB; Fujita Y; Batzloff MR; Good MF; Toth I Biopolymers; 2008; 90(5):611-6. PubMed ID: 18381625 [TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. Abdel-Aal AB; Batzloff MR; Fujita Y; Barozzi N; Faria A; Simerska P; Moyle PM; Good MF; Toth I J Med Chem; 2008 Jan; 51(1):167-72. PubMed ID: 18072728 [TBL] [Abstract][Full Text] [Related]
12. Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo. Powell TJ; Palath N; DeRome ME; Tang J; Jacobs A; Boyd JG Vaccine; 2011 Jan; 29(3):558-69. PubMed ID: 20951665 [TBL] [Abstract][Full Text] [Related]
14. Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine. Safari D; Marradi M; Chiodo F; Th Dekker HA; Shan Y; Adamo R; Oscarson S; Rijkers GT; Lahmann M; Kamerling JP; Penadés S; Snippe H Nanomedicine (Lond); 2012 May; 7(5):651-62. PubMed ID: 22630149 [TBL] [Abstract][Full Text] [Related]
15. Linear and branched polyacrylates as a delivery platform for peptide-based vaccines. Chandrudu S; Bartlett S; Khalil ZG; Jia Z; Hussein WM; Capon RJ; Batzloff MR; Good MF; Monteiro MJ; Skwarczynski M; Toth I Ther Deliv; 2016 Sep; 7(9):601-9. PubMed ID: 27582233 [TBL] [Abstract][Full Text] [Related]
16. Poly(hydrophobic amino acid)-Based Self-Adjuvanting Nanoparticles for Group A Azuar A; Li Z; Shibu MA; Zhao L; Luo Y; Shalash AO; Khalil ZG; Capon RJ; Hussein WM; Toth I; Skwarczynski M J Med Chem; 2021 Mar; 64(5):2648-2658. PubMed ID: 33529034 [TBL] [Abstract][Full Text] [Related]
17. Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity. Zaman M; Chandrudu S; Giddam AK; Reiman J; Skwarczynski M; McPhun V; Moyle PM; Batzloff MR; Good MF; Toth I Nanomedicine (Lond); 2014 Dec; 9(17):2613-24. PubMed ID: 25529566 [TBL] [Abstract][Full Text] [Related]
18. Engineering and evaluation of amyloid assemblies as a nanovaccine against the Chikungunya virus. Babych M; Bertheau-Mailhot G; Zottig X; Dion J; Gauthier L; Archambault D; Bourgault S Nanoscale; 2018 Nov; 10(41):19547-19556. PubMed ID: 30324958 [TBL] [Abstract][Full Text] [Related]
19. Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach. Kakwere H; Ingham ES; Allen R; Mahakian LM; Tam SM; Zhang H; Silvestrini MT; Lewis JS; Ferrara KW Bioconjug Chem; 2017 Nov; 28(11):2756-2771. PubMed ID: 28956907 [TBL] [Abstract][Full Text] [Related]
20. Development of poly(anhydride) nanoparticles loaded with peanut proteins: the influence of preparation method on the immunogenic properties. Rebouças Jde S; Irache JM; Camacho AI; Esparza I; Del Pozo V; Sanz ML; Ferrer M; Gamazo C Eur J Pharm Biopharm; 2012 Oct; 82(2):241-9. PubMed ID: 22782031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]